We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ULTOMIRIS (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
ULTOMIRIS
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
ravulizumab
Registration type
EOI
Indication
ULTOMIRIS is now also indicated for the treatment of patients with
- :
- Paroxysmal Nocturnal Haemoglobinuria (PNH)
- Atypical Haemolytic Uraemic Syndrome (aHUS)